Definium Therapeutics Inc at TD Cowen Healthcare Conference Transcript
Good morning everybody.
Thank you all for joining here with us today at the TDC 46th annual healthcare conference. My name is Athena Chen. I'm here on behalf of the biotech team. I'm pleased to introduce Rob Barrow, CEO of Dafinian, who will be presenting, on their company developing treatments for psychiatric disorders. Rob, please take it away.
All right, thanks so much, Tina.
All right.
So Depending Therapeutics lead program in the clinic, DT 120 is a proprietary form of LSD that we're developing and two of the biggest market indications and generalized anxiety disorder, major depressive disorder.
We're in an incredibly exciting year. We've got three pivotal studies rooting out across the course of 2026 and building on some really exciting data from phase two that we presented in 2024 initially and published last September in JAMMA.
When we talk about the market opportunity for these indications, A lot
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
